# Kamari Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kamari-pharma

- Industry: Biotechnology
- Headquarters: Ness Ziona, Israel
- Website: www.kamaripharma.com
- Total disclosed funding: $23M
- Latest round: Series A (Jun 3, 2025)
- Investors on record: 2

## About

Based in Israel, and founded in 2018, Kamari Pharma Ltd. operates as a developer of topical and oral drugs for treating skin diseases. In June 2025, Kamari Pharma Ltd. raised USD 23 million in series A funding co-led by new investor BRM Group and returning investor Pontifax Venture Capital, with participation from other unspecified investors. The company develops topical and oral medications based on patented small peptides that disrupt an ion channel TRPV3. These medications are designed to treat a variety of dermatological conditions, including keratoderma, Olmsted syndrome, pruritus, atopic dermatitis, ichthyosis, lichen simplex chronicus, and other severe inherited skin problems. The company will use the June 2025 funding for clinical development of KM023.

## Funding rounds

- Series A, Jun 3, 2025, $23M — BRM Group, Pontifax Venture Capital

## Investors

- BRM Group (https://capitalatlas.ai/funds/brm-group) — Series A
- Pontifax Venture Capital (https://capitalatlas.ai/funds/pontifax-venture-capital) — Series A